-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantargia Names IL-17 as Second Target for Preclinical CAN14 Antibody

PUBT·11/09/2026 06:38:54
Cantargia Names IL-17 as Second Target for Preclinical CAN14 Antibody
  • Cantargia identified IL-17 as the second target for CAN14, its bispecific antibody in preclinical development for chronic inflammatory diseases.
  • CAN14 is designed to combine IL1RAP-mediated pathway blockade with IL-17 inhibition to address multiple drivers of inflammation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cantargia AB published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.